search
Back to results

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
pioglitazone
CCX140-B
CCX140-B
Sponsored by
ChemoCentryx
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Diagnosed type 2 diabetes mellitus
  • Must have a body mass index ≥25 and <45 kg/m2, but if body mass index is ≥25 and <28 kg/m2, then waist circumference must be >94 cm for men and >80 cm for women
  • Must be on a stable dose of metformin for at least 8 weeks prior to randomization
  • Hemoglobin A1c (HbA1c) of 6.5 to 10.0% inclusive and fasting plasma glucose 135 to 270 mg/dL inclusive at Screening

Key Exclusion Criteria:

  • Type 1 diabetes mellitus or history of diabetic ketoacidosis
  • Received insulin treatment within 12 weeks of randomization
  • Received chronic (more than 7 days) systemic glucocorticoid treatment within 12 weeks of randomization
  • Received sulfonylurea, thiazolidinedione, exenatide, or any other glucose lowering treatment (other than metformin) within 8 weeks of randomization
  • Symptomatic congestive heart failure requiring prescription medication, clinically evident peripheral edema, poorly-controlled hypertension (systolic blood pressure >160 or diastolic blood pressure >100), history of unstable angina, myocardial infarction or stroke within 6 months of randomization, or chronic renal failure
  • History or presence of drug-induced myopathy, drug-induced creatine kinase elevation, or leukopenia (WBC count <3.5 x 10(9)/L)
  • History or presence of any form of cancer within the 5 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis
  • Fasting serum triglyceride >400 mg/dL

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Placebo Comparator

Active Comparator

Experimental

Experimental

Arm Label

Placebo

Active control

Active Study Medication (Group C)

Active Study Medication (Group D)

Arm Description

CCX140-B

CCX140-B

Outcomes

Primary Outcome Measures

Subject incidence of adverse events

Secondary Outcome Measures

Effect on fasting plasma glucose concentration

Full Information

First Posted
December 4, 2009
Last Updated
August 24, 2023
Sponsor
ChemoCentryx
search

1. Study Identification

Unique Protocol Identification Number
NCT01028963
Brief Title
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Official Title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
November 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ChemoCentryx

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and potential effectiveness of CCX140-B in subjects with Type 2 diabetes mellitus.
Detailed Description
The primary objective of this study is to evaluate the safety and tolerability of CCX140-B in subjects with Type 2 diabetes mellitus (T2DM) based on subject incidence of adverse events. The secondary objectives of this study include evaluation of the effect of CCX140-B on several measures of effectiveness commonly used in the evaluation of diabetes medications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
159 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Active control
Arm Type
Active Comparator
Arm Title
Active Study Medication (Group C)
Arm Type
Experimental
Arm Description
CCX140-B
Arm Title
Active Study Medication (Group D)
Arm Type
Experimental
Arm Description
CCX140-B
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo capsules once daily
Intervention Type
Drug
Intervention Name(s)
pioglitazone
Intervention Description
pioglitazone 30 mg tablet once daily
Intervention Type
Drug
Intervention Name(s)
CCX140-B
Intervention Description
CCX140-B capsules once daily (Group C)
Intervention Type
Drug
Intervention Name(s)
CCX140-B
Intervention Description
CCX140-B capsules once daily (Group D)
Primary Outcome Measure Information:
Title
Subject incidence of adverse events
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Effect on fasting plasma glucose concentration
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Diagnosed type 2 diabetes mellitus Must have a body mass index ≥25 and <45 kg/m2, but if body mass index is ≥25 and <28 kg/m2, then waist circumference must be >94 cm for men and >80 cm for women Must be on a stable dose of metformin for at least 8 weeks prior to randomization Hemoglobin A1c (HbA1c) of 6.5 to 10.0% inclusive and fasting plasma glucose 135 to 270 mg/dL inclusive at Screening Key Exclusion Criteria: Type 1 diabetes mellitus or history of diabetic ketoacidosis Received insulin treatment within 12 weeks of randomization Received chronic (more than 7 days) systemic glucocorticoid treatment within 12 weeks of randomization Received sulfonylurea, thiazolidinedione, exenatide, or any other glucose lowering treatment (other than metformin) within 8 weeks of randomization Symptomatic congestive heart failure requiring prescription medication, clinically evident peripheral edema, poorly-controlled hypertension (systolic blood pressure >160 or diastolic blood pressure >100), history of unstable angina, myocardial infarction or stroke within 6 months of randomization, or chronic renal failure History or presence of drug-induced myopathy, drug-induced creatine kinase elevation, or leukopenia (WBC count <3.5 x 10(9)/L) History or presence of any form of cancer within the 5 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis Fasting serum triglyceride >400 mg/dL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pirow MD
Organizational Affiliation
Amgen
Official's Role
Study Director
Facility Information:
City
Auchenflower
State/Province
Queensland
Country
Australia
City
Kippa-Ring
State/Province
Queensland
Country
Australia
City
Beroun
Country
Czechia
City
Hlucin
Country
Czechia
City
Neratovice
Country
Czechia
City
Novy Jicin
Country
Czechia
City
Ostrava
Country
Czechia
City
Pardubice
Country
Czechia
City
Prague
Country
Czechia
City
Prelouc
Country
Czechia
City
Slany
Country
Czechia
City
Uhersky Brod
Country
Czechia
City
Unicov
Country
Czechia
City
Usti nad Labem
Country
Czechia
City
Basenheim
Country
Germany
City
Berlin
Country
Germany
City
Cologne
Country
Germany
City
Dresden
Country
Germany
City
Heidelberg
Country
Germany
City
Mannheim
Country
Germany
City
Nuremberg
Country
Germany
City
Saarlouis
Country
Germany
City
Balatonfuered
Country
Hungary
City
Budapest
Country
Hungary
City
Satoraljaujhely
Country
Hungary
City
Szikszo
Country
Hungary
City
Christchurch
Country
New Zealand
City
Wellington
Country
New Zealand

12. IPD Sharing Statement

Learn more about this trial

A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs